Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Serra, Ryan ^a   Al Saidi, Abdel Ghany ^a   Angelov, Nikola ^b   Nares, Salvador ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; BACTERIUM LIPOPOLYSACCHARIDE; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; PHENYTOIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TUMOR NECROSIS FACTOR ALPHA;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ARTICLE; BACTERIAL VIRULENCE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MACROPHAGE; PROTEIN ANALYSIS; PROTEIN FUNCTION; SUPERNATANT;

BACTERIA (MICROORGANISMS);

EID: 77956505961     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-48     Document Type: Article

References (75)

1. Informational paper: Drug-associated gingival enlargement. A Dongari-Bagtzoglou, J Periodontol 2004 75 1424 1431 10.1902/jop.2004.75.10.1424 15562922
2. Diphenylhydantoin-induced gingival overgrowth in man: a clinicopathological study. M Penarrocha-Diago JV Bagan-Sebastian F Vera-Sempere, J Periodontol 1990 61 571 574 2213467
3. Diphenyldantoin and ion flux in lobster nerve. HH Pincus, Arch Neur 1972 26 4 10
4. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. M Bajpai LK Roskos DD Shen RH Levy, Drug Metab Dispos 1996 24 1401 1403 8971149
5. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy. CJ Lin MF Yen OY Hu MS Lin CH Hsiong HH Liou, Pharmacotherapy 2008 28 35 41 10.1592/phco.28.1.35 18154472
6. Effect of 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH) enantiomers, major metabolites of phenytoin, on the occurrence of chronic-gingival hyperplasia: in vivo and in vitro study. I Ieiri W Goto K Hirata A Toshitani S Imayama Y Ohyama H Yamada K Ohtsubo S Higuchi, Eur J Clin Pharmacol 1995 49 51 56 10.1007/BF00192358 8751021
7. Risk factors for drug-induced gingival overgrowth. RA Seymour JS Ellis JM Thomason, J Clin Periodontol 2000 27 217 223 10.1034/j.1600-051x.2000. 027004217.x 10783833
8. The pathogenesis of drug-induced gingival overgrowth. RA Seymour JM Thomason JS Ellis, J Clin Periodontol 1996 23 165 175 10.1111/j.1600-051X.1996. tb02072.x 8707974
9. Control of connective tissue metabolism by lasers. Recent developments and future prospects. RP Abergel CA Meeker TS Lam RM Dwyer MA Lesavoy J Uitto, J Amer Acad Dermatol 1984 11 1142 1150 10.1016/S0190-9622(84)80194-2
10. Diphenylhydantoin (dilantin) gingival hyperplasia: drug-induced abnormality of connective tissue. TM Hassell RC Page AS Narayanan CG Cooper, Proc Natl Acad Sci USA 1976 73 2909 2912 10.1073/pnas.73.8.2909 1066702
11. Phenytoin and cyclosporine A specifically regulate macrophage phenytoin and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible molecular mechanism of drug-induced gingival hyperplasia. A Iacopino D Doxey C Cutler S Nares K Stoever J Fojt A Gonzales RE Dill, J Periodontol 1997 68 73 83 9029455
12. Monocytes and Macrophages. S Nares SM Wahl, Measuring Immunity: Basic Science and Clinical Practice London: Elsevier, Lotze MT, Thomson AT, 1 2005 299 311
13. The multiple roles of macrophages in wound healing. DW Riches, The Molecular and Cellular Biology of Wound Repair New York: Plenum Press, Clark RAF, Henson PM, 1988 213 239
14. Surface phenotype analysis of human monocyte to macrophage differentiation. R Andreesen W Brugger C Scheinenbogen, J Leuk Biol 1990 47 490 497
15. General principles of healing pertinent to the periodontal problem. DV Messadi CN Bertolami, Dent Clin North Am 1991 35 443 457 1879568
16. Growth factors and cutaneous wound repair. P Martin J Hopkins-Woolley J McCluskey, Prog Growth Factor Res 1992 4 25 44 10.1016/0955-2235(92)90003-Z 1325207
17. Macrophage heterogeneity and differentiation. M Kreutz SW Krause A Rehm, Pres Immunol 1992 143 107 115 10.1016/0923-2494(92)80087-2
18. Significance of early healing events on periodontal repair: a review. UME Wikesjo RE Nilveus KA Selvig, J Periodontol 1992 63 158 165 1593409
19. Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. S Nares MC Ng RE Dill B Park CW Cutler AM Iacopino, J Periodontol 1996 67 271 278 8708960
20. Rapid myeloid cell transcriptional and proteomic responses to periodontopathogenic Porphyromonas gingivalis. S Nares NM Moutsopoulos N Angelov ZG Rangel PJ Munson N Sinha SM Wahl, Am J Pathol 2009 174 1400 1414 10.2353/ajpath.2009.080677 19264901
21. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. G Peng T Greenwell-Wild S Nares W Jin KJ Lei ZG Rangel PJ Munson SM Wahl, Blood 2007 110 393 400 10.1182/blood-2006-10-051763 17371941
22. The value of phenytoin plasma levels in the treatment of epilepsy. FJE Vajda, Med J Aust 1970 2 1074 1076 5491081
23. Clinical pharmacokinetics of anticonvulsants. EI Hvidberg M Dam, Clin Pharmacokinet 1976 1 161 188 10.2165/00003088-197601030-00001 797496
24. Plasma level monitoring of anticonvulsants. MJ Eadie, Clin Pharmacokinet 1976 1 52 66 10.2165/00003088-197601010-00005 797492
25. Anti-inflammatory and antioxidative effects of propofol on lipopolysaccharide-activated macrophages. RM Chen TG Chen TL Chen LL Lin CC Chang HC Chang CH Wu, Ann N Y Acad Sci 2005 1042 262 271 10.1196/annals.1338.030 15965071
26. Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. Y Rival N Benéteau V Chapuis T Taillandier F Lestienne E Dupont-Passelaigue JF Patoiseau FC Colpaert D Junquéro, DNA Cell Biol 2004 23 283 292 10.1089/104454904323090912 15169608
27. Transcriptional activation of MMP-13 by periodontal pathogenic LPS requires p38 MAP kinase. C Rossa Jr M Liu P Bronson KL Kirkwood, J Endotoxin Res 2007 13 85 93 10.1177/0968051907079118 17621549
28. Inflammatory responses of a macrophage/epithelial cell co-culture model to mono and mixed infections with Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia. C Bodet F Chandad D Grenier, Microbes Infec 2006 8 27 35 10.1016/j.micinf.2005.05.015 (Pubitemid 43139289)
29. Lipopolysaccharide induces matrix metalloproteinase-9 expression via a mitochondrial reactive oxygen species-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. CH Woo JH Lim JH Kim, J Immunol 2004 173 6973 6980 15557194
30. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. Y Zhang K Mc Cluskey K Fujii L Wahl, J Immunol 1998 161 3071 3076 9743373
31. Connective tissue metabolism and gingival overgrowth. PC Trackman A Kantarci, Crit Rev Oral Biol Med 2004 4 165 175 10.1177/154411130401500305
32. Macrophage subpopulations in gingival overgrowth induced by nifedipine and immunosuppressive medication. PK Nurmenniemi HE Pernu P Laukkanen ML Knuuttila, J Periodontol 2002 73 1323 1330 10.1902/jop.2002.73.11.1323 12479637
33. Factors influencing phenytoin-induced gingival enlargement. MP Majola ML McFadyen C Connolly YP Nair M Govender MH Laher, J Clin Periodontol 2000 27 506 512 10.1034/j.1600-051x.2000.027007506.x 10914892
34. Relationship of periodontal bacteria and Porphyromonas gingivalis fimA variations with phenytoin-induced gingival overgrowth. S Akiyama A Amano T Kato Y Takada KR Kimura I Morisaki, Oral Dis 2006 12 51 56 10.1111/j.1601-0825.2005. 01157.x 16390469
35. Grape seed extract suppresses lipopolysaccharide-induced matrix metalloproteinase (MMP) secretion by macrophages and inhibits human MMP-1 and -9 activities. VD La C Bergeron S Gafner D Grenier, J Periodontol 2009 80 1875 1882 10.1902/jop.2009.090251 19905958
36. Plasma and gingival crevicular fluid phenytoin concentrations as risk factors for gingival overgrowth. GN Güncü F Caglayan A Dinçel A Bozkurt S Saygi E Karabulut, J Periodontol 2006 77 2005 2010 10.1902/jop.2006.060103 17209785
37. Modulation of matrix metalloproteinase activities in periodontitis as a treatment of strategy. ME Ryan LM Golub, J Periodontol 2000 24 226 238 10.1034/j.1600-0757.2000.2240111.x
38. Gingival fibroblasts grown from cyclosporin-treated patients show a reduced production of matrix metalloproteinase-1 (MMP-1) compared with normal gingival fibroblasts, and cyclosporin down-regulates the production of MMP-1 stimulated by pro-inflammatory cytokines. TZ Sukkar JM Thomason TE Cawston R Lakey D Jones J Catterall RA Seymour, J Periodontal Res 2007 42 580 588 10.1111/j.1600-0765.2007.00986.x 17956473
39. Cyclosporin A inhibits collagenase gene expression via AP-1 and JNK suppression in human gingival fibroblasts. N Sugano K Ito S Murai, J Periodontal Res 1998 33 448 452 10.1111/j.1600-0765.1998.tb02343.x 9879517
40. Cyclosporin A inhibits production and activity of matrix metalloproteinases by gingival fibroblasts. G Bolzani R Della Coletta H Martelli Jnior H Martelli Jnior E Graner, J Periodontal Res 2000 35 51 58 10.1034/j.1600-0765.2000.035001051.x 10791709
41. Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. M Kataoka Y Shimizu K Kunikiyo Y Asahara K Yamashita M Ninomiya I Morisaki Y Ohsaki JI Kido T Nagata, J Cell Physiol 2000 182 351 358 10.1002/(SICI)1097-4652(200003)182:3<351::AID-JCP5>3.0.CO;2-U 10653601
42. Phenytoin and cyclosporin A suppress the expression of MMP-1, TIMP-1, and cathepsin L, but not cathepsin B in cultured gingival fibroblasts. H Yamada F Nishimura K Naruishi HH Chou S Takashiba GM Albright S Nares AM Iacopino Y Murayama, J Periodontol 2000 71 955 960 10.1902/jop.2000.71.6.955 10914799
43. The effects of cyclosporin on the collagenolytic activity of gingival fibroblasts. PL Hyland PS Traynor TT Myrillas JJ Marley GJ Linden P Winter N Leadbetter TE Cawston CR Irwin, J Periodontol 2003 74 437 445 10.1902/jop.2003.74.4.437 12747447
44. Cyclosporin-induced gingival overgrowth: correlation with dental plaque scores, gingivitis scores, and cyclosporin levels in serum and saliva. T McGaw S Lam J Coates, Oral Surg Oral Med Oral Pathol 1987 64 293 297 10.1016/0030-4220(87)90007-7 3477745
45. Cyclosporine-induced gingival overgrowth. WL Pan CP Chan CC Huang MK Lai, Transplant Proc 1992 24 1393 1394 1496598
46. Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. HE Pernu LM Pernu KR Huttunen PA Nieminen ML Knuuttila, J Periodontol 1992 63 548 553 1625155
47. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. GN King R Fullinfaw TJ Higgins RG Walker DM Francis D Wiesenfeld, J Clin Periodontol 1993 20 286 293 10.1111/j.1600-051X. 1993.tb00360.x 8473540
48. Immunohistochemical study of 30 cases of cyclosporin A-induced gingival overgrowth. F O'Valle FL Mesa M Gámez-Morales D Aguilar MD Caracuel MT Medina-Cano M Andjar J Lápez-Hidalgo R García del Moral, J Periodontol 1994 65 724 730 7608852
49. Iatrogenic gingival overgrowth in cardiac transplantation. JM Thomason RA Seymour JS Ellis PJ Kelly G Parry J Dark JR Idle, J Periodontol 1995 66 742 746 7473018
50. Gingival crevicular fluid and serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 levels in renal transplant patients undergoing different immunosuppressive therapy. G Emingil B Afacan T Tervahartiala H Toz G Atilla T Sorsa, J Clin Periodontol 2008 35 221 229 10.1111/j.1600-051X.2007.01192.x 18269661
51. Immunosuppression and gingival overgrowth: gene and protein expression profiles of collagen turnover in FK506-treated human gingival fibroblasts. N Gagliano C Moscheni C Dellavia G Stabellini VF Ferrario M Gioia, J Clin Periodontol 2005 32 167 173 10.1111/j.1600-051X.2005.00654.x 15691347
52. Cell interactions between human gingival fibroblasts and monocytes stimulate the production of matrix metalloproteinase-1 in gingival fibroblasts. H Domeij T Yucel-Lindberg T Modéer, J Periodontal Res 2006 41 108 117 10.1111/j.1600-0765.2005.00840.x 16499713
53. Sodium channel activity modulates multiple functions in microglia. JA Black S Liu SG Waxman, Glia 2009 57 1072 1081 10.1002/glia.20830 19115387
54. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. MJ Craner TG Damarjian S Liu BC Hains AC Lo JA Black J Newcombe ML Cuzner SG Waxman, Glia 2005 49 220 229 10.1002/glia.20112 15390090
55. Voltage-gated sodium channel blockers as immunomodulators. F Roselli P Livrea E Jirillo, Recent Patents CNS Drug Disc 2006 1 83 91 10.2174/ 157488906775245255
56. Cyclosporin A and phenytoin modulate inflammatory responses. AM Suzuki A Yoshimura Y Ozaki T Kaneko Y Hara, J Dent Res 2009 88 1131 1136 10.1177/0022034509350566 19897783
57. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling. M Koide S Kinugawa T Ninomiya T Mizoguchi T Yamashita K Maeda H Yasuda Y Kobayashi H Nakamura T Takahashi N Udagawa, J Bone Miner Res 2009 24 1469 1480 10.1359/jbmr.090302 19292614
58. The angiotensin-calcineurin-NFAT pathway mediates stretch-induced up-regulation of matrix metalloproteinases-2/-9 in atrial myocytes. E Saygili OR Rana C Meyer C Gemein MG Andrzejewski A Ludwig C Weber U Schotten A Krüttgen J Weis RH Schwinger K Mischke T Rassaf M Kelm P Schauerte, Basic Res Cardiol 2009 104 435 448 10.1007/s00395-008-0772-6 19148693
59. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. S Shiozawa K Tsumiyama, Cell Cycle 2009 8 1539 1543 10.4161/cc.8.10.8411 19395871
60. The regulation of matrix metalloproteinases and their inhibitors. IM Clark TE Swingler CL Sampieri DR Edwards, Int J Biochem Cell Biol 2008 40 1362 1378 10.1016/j.biocel.2007.12.006 18258475
61. Key structural features of ligands for activation of human pregnane X receptor. K Kobayashi S Yamagami T Higuchi M Hosokawa K Chiba, Drug Metab Dispos 2004 32 468 472 10.1124/dmd.32.4.468 15039302
62. Selective and differential binding of interleukin (1L)-1 alpha, IL-1 beta, IL-2, and IL-6 to glycosaminoglycans. L Ramsden CC Rider, Eur J Immunol 1992 22 3027 3031 10.1002/eji.1830221139 1425926
63. Sulfated glycosaminoglycans in Alzheimer's disease. AD Snow JP Willmer R Kisilevsky, Hum Pathol 1987 18 506 510 10.1016/S0046-8177(87)80036-9 3570282
64. Phenytoin potentiates interleukin-1 induced prostaglandin biosynthesis in human gingival fibroblasts. T Modeer G Brunius M Iinuma UH Lerner, Bri J Pharma 1992 106 574 578
65. TNF-alpha and IL-1b selectively induce expression of 92-kDa gelatinase by human macrophages. P Saren HG Welgus PT Kovanen, J Immunol 1996 157 4159 4165 8892653
66. Signal pathways involved in the production of MMP-1 and MMP-3 in human gingival fibroblasts. H Domeij T Yucel-Lindberg T Modeer, Eur J Oral Sci 2002 110 302 306 10.1034/j.1600-0722.2002.21247.x 12206592
67. Matrix metalloproteinease: a review. H Birkedal-Hansen WG Moore MK Bodden H Birkedal-Hansen, Crit Rev Oral Biol Med 1993 4 197 250 8435466
68. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. BJ Sugarman BB Aggarwal PE Hass IS Figari MA Palladino Jr HM Shepard, Science 1985 230 943 945 10.1126/science. 3933111 3933111
69. TNF-alpha inactivation of collagen receptors: implications for fibroblast function and fibrosis. DH Chou W Lee CA McCulloch, J Immunol 1996 156 4354 4362 8666807
70. Activation of p38alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. N Reunanen S-P Li M Ahonen M Foschi J Han V-M Kahari, J Biol Chem 2002 277 32360 32368 10.1074/jbc.M204296200 12060661
71. Tumor necrosis factor-{alpha} augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor - activated kinase 1 (TAK1)-dependent signaling pathway. AK Srivastava X Qin N Wedhas M Arnush TA Linkhart RB Chadwick A Kumar, J Biol Chem 2007 282 35113 35124 10.1074/jbc.M705329200 17897957
72. 2+ are required for endotoxin-stimulated TNF-alpha release by rat Kupffer cells. SN Lichtman J Wang C Zhang JJ Lemasters, Am J Physiol 1996 271 920 G928 8944708
73. Activation by bacterial lipopolysaccharide causes changes in the cytosolic free calcium concentration in single peritoneal macrophages. O Letari S Nicosia C Chiavaroli P Vacher W Schlegel, J Immunol 1991 147 980 983 1907309
74. 2+- and protein kinase C-dependent signaling pathway for nuclear factor-kappa B activation, inducible nitric oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages. X Zhou W Yang J Li, J Biol Chem 2006 281 31337 31347 10.1074/jbc.M602739200 16923814
75. Role of transient receptor potential vanilloid 2 in LPS-induced cytokine production in macrophages. K Yamashiro T Sasano K Tojo I Namekata J Kurokawa N Sawada T Suganami Y Kamei H Tanaka N Tajima K Utsunomiya Y Ogawa T Furukawa, Biochem Biophys Res Commun 2010 398 284 289 10.1016/j.bbrc.2010.06.082 20599720